Denali Therapeutics Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Public

  • Employees
  • 447

Employees

  • Stock Symbol
  • DNLI

Stock Symbol

  • Investments
  • 3

  • Share Price
  • $23.40
  • (As of Tuesday Closing)

Denali Therapeutics General Information

Description

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Corporate Office
  • 161 Oyster Point Boulevard
  • South San Francisco, CA 94080
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Denali Therapeutics Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$23.40 $16.89 $15.45 - $33.31 $3.23B 138M 1.16M -$1.06

Denali Therapeutics Financials Summary

In Thousands,
USD
TTM 31-Dec-2023 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 1,910,349 1,910,349 2,732,969 4,472,868
Revenue 330,531 330,531 108,463 48,661
EBITDA (330,361) (287,158)
Net Income (145,224) (145,224) (325,991) (290,581)
Total Assets 1,153,917 1,153,917 1,460,242 1,404,162
Total Debt 44,981 44,981 60,350 64,007
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Denali Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Denali Therapeutics‘s full profile, request access.

Request a free trial

Denali Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Denali Therapeutics‘s full profile, request access.

Request a free trial

Denali Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat
Biotechnology
South San Francisco, CA
447 As of 2023
00.000
000000000 00.000

000000

it in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sin
0000 000000000
South San Francisco, CA
000 As of 0000
00000
000000 - 000 00000

000000

didunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud e
0000 000000000
Berwyn, PA
0 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Denali Therapeutics Competitors (62)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Alector Formerly VC-backed South San Francisco, CA 000 00000 000000 - 000 00000
Annovis Bio Formerly VC-backed Berwyn, PA 0 00000 00000000 00000
CRISPR Therapeutics Formerly VC-backed Zug, Switzerland 000 00000 000000000 00000
Sangamo Therapeutics Formerly VC-backed Brisbane, CA 000 00000 000000000 00000
Avidity Biosciences Formerly VC-backed La Jolla, CA 000 00000 00000000 00000
You’re viewing 5 of 62 competitors. Get the full list »

Denali Therapeutics Patents

Denali Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240025915-A1 Solid forms of 4-(3,3-difluoro-2,2-dimethyl-propanoyl)-3,5-dihydro-2h-pyrido[3,4-f][1,4]oxazepine-9-carbonitrile Pending 25-Jul-2022 0000000000 0
US-20230271978-A1 Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide Pending 12-Jan-2022 0000000000
CA-3229542-A1 Anti-her2 antibodies and methods of use thereof Pending 25-Aug-2021
AU-2022333088-A1 Anti-her2 antibodies and methods of use thereof Pending 25-Aug-2021
AU-2022302171-A1 Oligonucleotide conjugates targeted to the transferrin receptor Pending 01-Jul-2021
To view Denali Therapeutics’s complete patent history, request access »

Denali Therapeutics Executive Team (14)

Name Title Board Seat Contact Info
Ryan Watts Ph.D President, Chief Executive Officer & Co-Founder
Alexander Schuth Co-Founder & Chief Operating and Financial Officer
Dana Andersen Ph.D Chief Technical and Manufacturing Officer
Cindy Dunkle Chief People Officer
Joe Lewcock Chief Scientific Officer
You’re viewing 5 of 14 executive team members. Get the full list »

Denali Therapeutics Board Members (14)

Name Representing Role Since
David Schenkein MD ARCH Venture Partners Board Member 000 0000
Douglas Cole MD Flagship Pioneering Board Member 000 0000
Erik Harris Self Board Member 000 0000
Jay Flatley Self Board Member 000 0000
Jennifer Cook Denali Therapeutics Board Member 000 0000
You’re viewing 5 of 14 board members. Get the full list »

Denali Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Denali Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Denali Therapeutics‘s full profile, request access.

Request a free trial

Denali Therapeutics Investments & Acquisitions (3)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
F-star Gamma 30-May-2018 0000000000 00000 Biotechnology 0000 0000
Incro Pharmaceuticals 25-Aug-2016 0000000000 00000 Biotechnology 000000 00
F-star Gamma 05-Jun-2016 Secondary Transaction - Private 000 Biotechnology 0000 0000
To view Denali Therapeutics’s complete investments and acquisitions history, request access »

Denali Therapeutics ESG

Risk Overview

Risk Rating

Updated December, 01, 2023

24.93 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,605

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 870

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 386

Rank

00.00

Percentile

To view Denali Therapeutics’s complete esg history, request access »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »